Thus, the concurrent administration of PD-1 inhibitors and anti-VEGF medicines has the potential to enhance the anti-tumor response by synergistically modulating the function of effector T cells and normalizing the tumor vasculature inside the TME, thereby converting “cold tumors” into “hot tumors”. Here, VEGFA is linked to neoplasm.